(NASDAQ: CNTA) Centessa Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.
Centessa Pharmaceuticals's earnings in 2026 is -$197,532,000.On average, 15 Wall Street analysts forecast CNTA's earnings for 2026 to be -$271,777,848, with the lowest CNTA earnings forecast at -$327,190,666, and the highest CNTA earnings forecast at -$261,298,102. On average, 13 Wall Street analysts forecast CNTA's earnings for 2027 to be -$288,811,300, with the lowest CNTA earnings forecast at -$419,591,734, and the highest CNTA earnings forecast at -$186,641,501.
In 2028, CNTA is forecast to generate -$232,656,553 in earnings, with the lowest earnings forecast at -$346,882,697 and the highest earnings forecast at $69,787,692.